We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Team of the Diabetes and Metabolism group at VHIR
Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.
Retinitis pigmentosa is an inherited disease characterised by the progressive loss of retinal photoreceptors and, consequently, of vision. Currently, patients affected by this condition do not have effective treatments to stop the disease, which has a significant impact on quality of life. With the aim of identifying new therapeutic strategies to address this pathology, the Fundación Lucha contra la Ceguera (FUNDALUCE) has awarded a grant to a project led by Dr. Maria Llorián-Salvador, principal investigator of the Diabetes and Metabolism research group at Vall d’Hebron Research Institute (VHIR).
Although retinitis pigmentosa is caused by more than 80 genetic mutations that trigger the death of retinal photoreceptors, recent studies suggest that sustained inflammation plays a key role in the progression of the disease. This observation opens the door to new therapeutic approaches based on modulation of the immune system.
The project funded by FUNDALUCE focuses on a specific type of immune cell: regulatory T cells (Treg). These cells play a crucial role in controlling the inflammatory response and are currently being studied as a therapeutic tool in neurodegenerative diseases such as Alzheimer’s disease or multiple sclerosis. The VHIR team has previously obtained preliminary results in animal models*, showing that the absence of Treg cells accelerates retinal damage, while their reintroduction can reduce inflammation and help preserve neurons.
The research will explore two complementary intervention strategies: the systemic expansion of Treg cells through treatments that stimulate their proliferation across the body, and a local therapy approach using viral vectors designed to increase the presence of Treg cells specifically in the retina and the optic nerve. In addition, the team will study the mechanisms by which Treg cells prevent retinal degeneration.
As Dr. Maria Llorián-Salvador explains, “this project explores an innovative therapeutic approach based on inflammation regulation, which is already being studied in clinical trials for other diseases. This will help accelerate the clinical implementation of this potential new treatment for retinitis pigmentosa, with the aim of preserving vision and improving the quality of life of those affected”.
The FUNDALUCE Grant is an annual recognition of talent and excellence in biomedical research, particularly in the field of inherited retinal dystrophies. This award seeks to support high-impact scientific projects that contribute significantly to the understanding, treatment or prevention of these diseases.
The project was selected following a rigorous evaluation process by the State Research Agency (AEI), which is part of the Ministry of Science, Innovation and Universities, as well as by the Foundation’s Expert Advisory Committee (CAE), and was ultimately ratified by the FUNDALUCE Board of Trustees.
*Institutional Statement on the Use of Research Animals
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.